{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T21:04:19Z","timestamp":1781816659525,"version":"3.54.5"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03312-6","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T07:33:49Z","timestamp":1756107229000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeting the CD47-SIRPalpha checkpoint in multiple myeloma"],"prefix":"10.1007","volume":"16","author":[{"given":"Tao Ming","family":"Sim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee Joo","family":"Chng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"de Mel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"issue":"8","key":"3312_CR1","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1002\/ajh.25117","volume":"93","author":"SV Rajkumar","year":"2018","unstructured":"Rajkumar SV, Multiple myeloma. 2018 update on diagnosis, risk-stratification, and management. Am J Hematol. 2018;93(8):1091\u2013110.","journal-title":"Am J Hematol"},{"issue":"24","key":"3312_CR2","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1182\/blood.2020006540","volume":"136","author":"K Nakamura","year":"2020","unstructured":"Nakamura K, Smyth MJ, Martinet L. Cancer immunoediting and immune dysregulation in multiple myeloma. Blood. 2020;136(24):2731\u201340.","journal-title":"Blood"},{"issue":"10272","key":"3312_CR3","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Pawlyn C, Yong K. L., multiple myeloma. Lancet. 2021;397(10272):410\u201327.","journal-title":"Lancet"},{"issue":"5","key":"3312_CR4","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. cell. 2011;144(5):646\u201374.","journal-title":"cell"},{"issue":"2","key":"3312_CR5","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3390\/cancers13020217","volume":"13","author":"A Garc\u00eda-Ortiz","year":"2021","unstructured":"Garc\u00eda-Ortiz A, Rodr\u00edguez-Garc\u00eda Y, Encinas J, Maroto-Mart\u00edn E, Castellano E, Teixid\u00f3 J, Mart\u00ednez-L\u00f3pez J. The role of tumor microenvironment in multiple myeloma development and progression. Cancers (Basel). 2021;13(2):217.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"3312_CR6","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1158\/1078-0432.CCR-19-2111","volume":"26","author":"AD Cohen","year":"2020","unstructured":"Cohen AD, Raje N, Fowler JA, Mezzi K, Scott EC, Dhodapkar MV. How to train your T cells: overcoming immune dysfunction in multiple myeloma. Clin Cancer Res. 2020;26(7):1541\u201354.","journal-title":"Clin Cancer Res"},{"issue":"18","key":"3312_CR7","doi-asserted-by":"publisher","first-page":"8444","DOI":"10.1158\/0008-5472.CAN-06-4230","volume":"67","author":"YM El-Sherbiny","year":"2007","unstructured":"El-Sherbiny YM, Meade JL, Holmes TD, McGonagle D, Mackie SL, Morgan AW, Cook G, Feyler S, Richards SJ, Davies FE. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res. 2007;67(18):8444\u20139.","journal-title":"Cancer Res"},{"issue":"2","key":"3312_CR8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1182\/blood.2019004537","volume":"136","author":"C Perez","year":"2020","unstructured":"Perez C, Botta C, Zabaleta A, Puig N, Cedena MT, Goicoechea I, Alameda D, San Jos\u00e9-Eneriz E, Merino J, Rodr\u00edguez-Otero P, Maia C, Alignani D, Maiso P, Manrique I, Lara-Astiaso D, Vilas-Zornoza A, Sarvide S, Riillo C, Rossi M, Rosi\u00f1ol L, Oriol A, Blanchard MJ, Rios R, Sureda A, Martin J, Martinez R, Bargay J, de la Rubia J, Hernandez MT, Martinez-Lopez J, Orfao A, Agirre X, Prosper F, Mateos MV, Lahuerta JJ, Blade J, San-Miguel JF, Paiva B. Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma. Blood. 2020;136(2):199\u2013209.","journal-title":"Blood"},{"issue":"22","key":"3312_CR9","doi-asserted-by":"publisher","first-page":"5654","DOI":"10.3390\/cancers14225654","volume":"14","author":"SS Wang","year":"2022","unstructured":"Wang SS, Chng WJ, Liu H, de Mel S. Tumor-Associated macrophages and related myelomonocytic cells in the tumor microenvironment of multiple myeloma. Cancers. 2022;14(22):5654.","journal-title":"Cancers"},{"issue":"14","key":"3312_CR10","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.3390\/cancers13143597","volume":"13","author":"E Cencini","year":"2021","unstructured":"Cencini E, Fabbri A, Sicuranza A, Gozzetti A, Bocchia M. The role of tumor-associated macrophages in hematologic malignancies. Cancers. 2021;13(14):3597.","journal-title":"Cancers"},{"issue":"1","key":"3312_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41392-021-00484-9","volume":"6","author":"X Xiang","year":"2021","unstructured":"Xiang X, Wang J, Lu D, Xu X. Targeting tumor-associated macrophages to synergize tumor immunotherapy. Signal Transduct Target Therapy. 2021;6(1):75.","journal-title":"Signal Transduct Target Therapy"},{"issue":"1","key":"3312_CR12","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s10555-020-09943-1","volume":"40","author":"KS Opperman","year":"2021","unstructured":"Opperman KS, Vandyke K, Psaltis PJ, Noll JE, Zannettino AC. Macrophages in multiple myeloma: key roles and therapeutic strategies. Cancer Metastasis Rev. 2021;40(1):273\u201384.","journal-title":"Cancer Metastasis Rev"},{"issue":"17","key":"3312_CR13","first-page":"3625","volume":"114","author":"Y Zheng","year":"2009","unstructured":"Zheng Y, Cai Z, Wang S, Zhang X, Qian J, Hong S, Li H, Wang M, Yang J, Yi Q. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug\u2013induced apoptosis. Blood J Am Soc Hematol. 2009;114(17):3625\u20138.","journal-title":"Blood J Am Soc Hematol"},{"issue":"6","key":"3312_CR14","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","volume":"19","author":"DG DeNardo","year":"2019","unstructured":"DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol. 2019;19(6):369\u201382.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"3312_CR15","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3390\/cancers12020305","volume":"12","author":"J Sun","year":"2020","unstructured":"Sun J, Muz B, Alhallak K, Markovic M, Gurley S, Wang Z, Guenthner N, Wasden K, Fiala M, King J. Targeting CD47 as a novel immunotherapy for multiple myeloma. Cancers (Basel). 2020;12(2):305.","journal-title":"Cancers (Basel)"},{"issue":"6621","key":"3312_CR16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/386181a0","volume":"386","author":"A Kharitonenkov","year":"1997","unstructured":"Kharitonenkov A, Chen Z, Sures I, Wang H, Schilling J, Ullrich A. A family of proteins that inhibit signalling through tyrosine kinase receptors. Nature. 1997;386(6621):181\u20136.","journal-title":"Nature"},{"issue":"35","key":"3312_CR17","doi-asserted-by":"publisher","first-page":"22719","DOI":"10.1074\/jbc.273.35.22719","volume":"273","author":"A Veillette","year":"1998","unstructured":"Veillette A, Thibaudeau E, Latour S. High expression of inhibitory receptor SHPS-1 and its association with protein-tyrosine phosphatase SHP-1 in macrophages. J Biol Chem. 1998;273(35):22719\u201328.","journal-title":"J Biol Chem"},{"issue":"2","key":"3312_CR18","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1074\/jbc.274.2.559","volume":"274","author":"P Jiang","year":"1999","unstructured":"Jiang P, Lagenaur CF, Narayanan V. Integrin-associated protein is a ligand for the P84 neural adhesion molecule. J Biol Chem. 1999;274(2):559\u201362.","journal-title":"J Biol Chem"},{"issue":"5","key":"3312_CR19","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1083\/jcb.200708043","volume":"180","author":"RK Tsai","year":"2008","unstructured":"Tsai RK, Discher DE. Inhibition of self engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. J Cell Biol. 2008;180(5):989\u20131003.","journal-title":"J Cell Biol"},{"issue":"7","key":"3312_CR20","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1111\/j.1476-5381.2012.02099.x","volume":"167","author":"E Sick","year":"2012","unstructured":"Sick E, Jeanne A, Schneider C, Dedieu S, Takeda K, Martiny L. CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest. Br J Pharmacol. 2012;167(7):1415\u201330.","journal-title":"Br J Pharmacol"},{"issue":"8","key":"3312_CR21","doi-asserted-by":"publisher","first-page":"e943","DOI":"10.1002\/ctm2.943","volume":"12","author":"R Bouwstra","year":"2022","unstructured":"Bouwstra R, van Meerten T, Bremer E. CD47-SIRP\u03b1 blocking-based immunotherapy: current and prospective therapeutic strategies. Clin Transl Med. 2022;12(8):e943.","journal-title":"Clin Transl Med"},{"key":"3312_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40364-021-00327-3","volume":"9","author":"Y Qiu","year":"2021","unstructured":"Qiu Y, Chen T, Hu R, Zhu R, Li C, Ruan Y, Xie X, Li Y. Next frontier in tumor immunotherapy: macrophage-mediated immune evasion. Biomark Res. 2021;9:1\u201319.","journal-title":"Biomark Res"},{"issue":"3","key":"3312_CR23","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1002\/cam4.1894","volume":"8","author":"JH Wang","year":"2019","unstructured":"Wang JH, Huang ST, Zhang L, Liu ZG, Liang RX, Jiang SW, Jiang YN, Yu XJ, Jiang YC, Li XZ. Combined prognostic value of the cancer stem cell markers CD47 and CD133 in esophageal squamous cell carcinoma. Cancer Med. 2019;8(3):1315\u201325.","journal-title":"Cancer Med"},{"issue":"3","key":"3312_CR24","first-page":"3249","volume":"18","author":"J Yuan","year":"2019","unstructured":"Yuan J, Shi X, Chen C, He H, Liu L, Wu J, Yan H. High expression of CD47 in triple negative breast cancer is associated with epithelial\u2013mesenchymal transition and poor prognosis. Oncol Lett. 2019;18(3):3249\u201355.","journal-title":"Oncol Lett"},{"issue":"1","key":"3312_CR25","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3892\/ol.2017.6257","volume":"14","author":"T Sudo","year":"2017","unstructured":"Sudo T, Takahashi Y, Sawada G, Uchi R, Mimori K, Akagi Y. Significance of CD47 expression in gastric cancer. Oncol Lett. 2017;14(1):801\u20139.","journal-title":"Oncol Lett"},{"issue":"2","key":"3312_CR26","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","volume":"138","author":"R Majeti","year":"2009","unstructured":"Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD, van Rooijen N, Weissman IL. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138(2):286\u201399.","journal-title":"Cell"},{"issue":"5","key":"3312_CR27","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","volume":"142","author":"MP Chao","year":"2010","unstructured":"Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 2010;142(5):699\u2013713.","journal-title":"Cell"},{"issue":"6","key":"3312_CR28","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/j.1365-2141.2007.06729.x","volume":"138","author":"JM Rendtlew Danielsen","year":"2007","unstructured":"Rendtlew Danielsen JM, Knudsen LM, Dahl IM, Lodahl M, Rasmussen T. Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma. Br J Haematol. 2007;138(6):756\u201360.","journal-title":"Br J Haematol"},{"issue":"9","key":"3312_CR29","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1002\/cam4.2332","volume":"8","author":"H Yang","year":"2019","unstructured":"Yang H, Shao R, Huang H, Wang X, Rong Z, Lin Y. Engineering macrophages to phagocytose cancer cells by blocking the CD47\/SIRP\u0251 axis. Cancer Med. 2019;8(9):4245\u201353.","journal-title":"Cancer Med"},{"issue":"12","key":"3312_CR30","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1038\/leu.2012.141","volume":"26","author":"D Kim","year":"2012","unstructured":"Kim D, Wang J, Willingham Sa, Martin R, Wernig G, Weissman I. Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia. 2012;26(12):2538\u201345.","journal-title":"Leukemia"},{"key":"3312_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2022.100070","volume":"13","author":"R Maute","year":"2022","unstructured":"Maute R, Xu J, Weissman IL. CD47-SIRP\u03b1-targeted therapeutics: status and prospects. Immuno-Oncology and Technology. 2022;13: 100070.","journal-title":"Immuno-Oncology and Technology"},{"key":"3312_CR32","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ejca.2017.02.013","volume":"76","author":"K Weiskopf","year":"2017","unstructured":"Weiskopf K. Cancer immunotherapy targeting the CD47\/SIRP\u03b1 axis. Eur J Cancer. 2017;76:100\u20139.","journal-title":"Eur J Cancer"},{"issue":"5","key":"3312_CR33","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1182\/blood.V99.5.1745","volume":"99","author":"F Zhan","year":"2002","unstructured":"Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 2002;99(5):1745\u201357.","journal-title":"Blood"},{"issue":"12","key":"3312_CR34","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.3324\/haematol.2019.227579","volume":"105","author":"N Rastgoo","year":"2020","unstructured":"Rastgoo N, Wu J, Liu A, Pourabdollah M, Atenafu EG, Reece D, Chen W, Chang H. Targeting CD47\/TNFAIP8 by miR-155 overcomes drug resistance and inhibits tumor growth through induction of phagocytosis and apoptosis in multiple myeloma. Haematologica. 2020;105(12):2813.","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"3312_CR35","doi-asserted-by":"publisher","first-page":"9937","DOI":"10.1182\/blood-2022-164755","volume":"140","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Sheng Z, Xia J, Ye C, Liu Y, Wang Z, Hayslip J, Zhu A. Exploration of the therapeutic effects of CD47 and CD38 antibody combination in relapsed or refractory multiple myeloma (rrMM) and the correlation with CD47 and CD38 expression. Blood. 2022;140(Supplement 1):9937\u20138.","journal-title":"Blood"},{"key":"3312_CR36","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.omto.2022.03.002","volume":"25","author":"Z Zhou","year":"2022","unstructured":"Zhou Z, Wang Z, Gao J, Lin Z, Wang Y, Shan P, Li M, Zhou T, Li P. Noncoding RNA-mediated macrophage and cancer cell crosstalk in hepatocellular carcinoma. Mol Ther Oncolytics. 2022;25:98\u2013120.","journal-title":"Mol Ther Oncolytics"},{"key":"3312_CR37","doi-asserted-by":"publisher","first-page":"103211","DOI":"10.1016\/j.critrevonc.2020.103211","volume":"159","author":"LL Chong","year":"2021","unstructured":"Chong LL, Soon YY, Soekojo CY, Ooi M, Chng WJ, de Mel S. Daratumumab-based induction therapy for multiple myeloma: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021;159:103211.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3312_CR38","doi-asserted-by":"crossref","unstructured":"Kambhampati S, Wen KW, Sung V, Wong SWK, Martin TG, Wolf JL, Shah N, Wiita A. Investigating macrophage function as a mechanism of resistance to daratumumab in relapsed refractory multiple myeloma patients. In American Society of Clinical Oncology. 2020.","DOI":"10.1200\/JCO.2020.38.15_suppl.e20547"},{"issue":"1","key":"3312_CR39","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41408-024-01096-6","volume":"14","author":"B Ziccheddu","year":"2024","unstructured":"Ziccheddu B, Giannotta C, D\u2019Agostino M, Bertuglia G, Saraci E, Oliva S, Genuardi E, Papadimitriou M, Diamond B, Corradini P, Coffey D, Landgren O, Bolli N, Bruno B, Boccadoro M, Massaia M, Maura F, Larocca A. Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma. Blood Cancer J. 2024;14(1):117.","journal-title":"Blood Cancer J"},{"issue":"12","key":"3312_CR40","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1038\/s43018-023-00657-1","volume":"4","author":"F Maura","year":"2023","unstructured":"Maura F, Boyle EM, Coffey D, Maclachlan K, Gagler D, Diamond B, Ghamlouch H, Blaney P, Ziccheddu B, Cirrincione A, Chojnacka M, Wang Y, Siegel A, Hoffman JE, Kazandjian D, Hassoun H, Guzman E, Mailankody S, Shah UA, Tan C, Hultcrantz M, Scordo M, Shah GL, Landau H, Chung DJ, Giralt S, Zhang Y, Arbini A, Gao Q, Roshal M, Dogan A, Lesokhin AM, Davies FE, Usmani SZ, Korde N, Morgan GJ, Landgren O. Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens. Nat Cancer. 2023;4(12):1660\u201374.","journal-title":"Nat Cancer"},{"issue":"10","key":"3312_CR41","doi-asserted-by":"publisher","first-page":"e0187262","DOI":"10.1371\/journal.pone.0187262","volume":"12","author":"GH Lin","year":"2017","unstructured":"Lin GH, Chai V, Lee V, Dodge K, Truong T, Wong M, Johnson LD, Linderoth E, Pang X, Winston J. TTI-621 (SIRP\u03b1Fc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets. PLoS ONE. 2017;12(10):e0187262.","journal-title":"PLoS ONE"},{"issue":"4","key":"3312_CR42","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.leukres.2004.09.005","volume":"29","author":"Y Kikuchi","year":"2005","unstructured":"Kikuchi Y, Uno S, Kinoshita Y, Yoshimura Y, Iida S-i, Wakahara Y, Tsuchiya M, Yamada-Okabe H, Fukushima N. Apoptosis inducing bivalent single-chain antibody fragments against CD47 showed antitumor potency for multiple myeloma. Leuk Res. 2005;29(4):445\u201350.","journal-title":"Leuk Res"},{"key":"3312_CR43","doi-asserted-by":"publisher","first-page":"106949","DOI":"10.1016\/j.leukres.2022.106949","volume":"122","author":"Y Yue","year":"2022","unstructured":"Yue Y, Cao Y, Wang F, Zhang N, Qi Z, Mao X, Guo S, Li F, Guo Y, Lin Y, Dong W, Huang Y, Gu W. Bortezomib-resistant multiple myeloma patient-derived xenograft is sensitive to anti-CD47 therapy. Leuk Res. 2022;122:106949.","journal-title":"Leuk Res"},{"issue":"16","key":"3312_CR44","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1182\/blood-2009-03-211920","volume":"114","author":"A Kukreja","year":"2009","unstructured":"Kukreja A, Radfar S, Sun BH, Insogna K, Dhodapkar MV. Dominant role of CD47-thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease. Blood. 2009;114(16):3413\u201321.","journal-title":"Blood"},{"issue":"4","key":"3312_CR45","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1158\/0008-5472.CAN-10-2238","volume":"71","author":"MP Chao","year":"2011","unstructured":"Chao MP, Alizadeh AA, Tang C, Jan M, Weissman-Tsukamoto R, Zhao F, Park CY, Weissman IL, Majeti R. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res. 2011;71(4):1374\u201384.","journal-title":"Cancer Res"},{"issue":"18","key":"3312_CR46","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1182\/blood-2011-02-338020","volume":"118","author":"MP Chao","year":"2011","unstructured":"Chao MP, Tang C, Pachynski RK, Chin R, Majeti R, Weissman IL. Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood. 2011;118(18):4890\u2013901.","journal-title":"Blood"},{"issue":"12","key":"3312_CR47","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1038\/leu.2012.141","volume":"26","author":"D Kim","year":"2012","unstructured":"Kim D, Wang J, Willingham SB, Martin R, Wernig G, Weissman IL. Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia. 2012;26(12):2538\u201345.","journal-title":"Leukemia"},{"issue":"27","key":"3312_CR48","doi-asserted-by":"publisher","first-page":"11103","DOI":"10.1073\/pnas.1305569110","volume":"110","author":"D Tseng","year":"2013","unstructured":"Tseng D, Volkmer J-P, Willingham SB, Contreras-Trujillo H, Fathman JW, Fernhoff NB, Seita J, Inlay MA, Weiskopf K, Miyanishi M. Anti-CD47 antibody\u2013mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc Natl Acad Sci. 2013;110(27):11103\u20138.","journal-title":"Proc Natl Acad Sci"},{"key":"3312_CR49","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1182\/blood-2021-152896","volume":"138","author":"WC Wilson","year":"2021","unstructured":"Wilson WC, Richards JO, Andrejeva G, Capoccia BJ, Puro RJ, Donio MJ, Hiebsch RR, Kashyap AK, Pereira DS. AO-176, a differentiated clinical-stage anti-CD47 antibody, demonstrates potent anti-tumor activity across multiple preclinical models of b cell neoplasms. Blood. 2021;138:2277.","journal-title":"Blood"},{"issue":"4","key":"3312_CR50","doi-asserted-by":"publisher","first-page":"712","DOI":"10.4049\/jimmunol.2001019","volume":"206","author":"G Andrejeva","year":"2021","unstructured":"Andrejeva G, Capoccia BJ, Hiebsch RR, Donio MJ, Darwech IM, Puro RJ, Pereira DS. Novel SIRP\u03b1 antibodies that induce single-agent phagocytosis of tumor cells while preserving T cells. J Immunol. 2021;206(4):712\u201321.","journal-title":"J Immunol"},{"issue":"11","key":"3312_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11111738","volume":"11","author":"H Handa","year":"2019","unstructured":"Handa H, Murakami Y, Ishihara R, Kimura-Masuda K, Masuda Y. The role and function of microrna in the pathogenesis of multiple myeloma. Cancers. 2019;11(11): 1738.","journal-title":"Cancers"},{"issue":"3","key":"3312_CR52","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/bjh.16548","volume":"190","author":"P Storti","year":"2020","unstructured":"Storti P, Vescovini R, Costa F, Marchica V, Toscani D, Dalla Palma B, Craviotto L, Malavasi F, Giuliani N. CD14\u2009+\u2009CD16\u2009+\u2009monocytes are involved in daratumumab-mediated myeloma cells killing and in anti\u2010CD47 therapeutic strategy. Br J Haematol. 2020;190(3):430\u20136.","journal-title":"Br J Haematol"},{"issue":"10","key":"3312_CR53","doi-asserted-by":"publisher","first-page":"e0187262","DOI":"10.1371\/journal.pone.0187262","volume":"12","author":"GHY Lin","year":"2017","unstructured":"Lin GHY, Chai V, Lee V, Dodge K, Truong T, Wong M, Johnson LD, Linderoth E, Pang X, Winston J, Petrova PS, Uger RA, Viller NN. TTI-621 (SIRP\u03b1Fc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets. PLoS ONE. 2017;12(10):e0187262.","journal-title":"PLoS ONE"},{"key":"3312_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01380","volume":"9","author":"MP Chao","year":"2020","unstructured":"Chao MP, Takimoto CH, Feng DD, McKenna K, Gip P, Liu J, Volkmer J-P, Weissman IL, Majeti R. Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies. Front Oncol. 2020;9: 1380.","journal-title":"Front Oncol"},{"issue":"9","key":"3312_CR55","doi-asserted-by":"publisher","first-page":"e0137345","DOI":"10.1371\/journal.pone.0137345","volume":"10","author":"J Liu","year":"2015","unstructured":"Liu J, Wang L, Zhao F, Tseng S, Narayanan C, Shura L, Willingham S, Howard M, Prohaska S, Volkmer J. Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PLoS ONE. 2015;10(9):e0137345.","journal-title":"PLoS ONE"},{"key":"3312_CR56","doi-asserted-by":"crossref","unstructured":"Sallman DA, Al Malki MM, Asch AS, Wang ES, Jurcic JG, Bradley TJ, Flinn IW, Pollyea DA, Kambhampati S, Tanaka TN. Magrolimab in combination with azacitidine for untreated higher-risk myelodysplastic syndromes (HR-MDS): 5F9005 phase 1b study results. In American Society of Clinical Oncology. 2022.","DOI":"10.1016\/S2152-2650(22)00918-1"},{"key":"3312_CR57","doi-asserted-by":"publisher","first-page":"S295","DOI":"10.1016\/S2152-2650(24)01162-5","volume":"24","author":"A Basharat","year":"2024","unstructured":"Basharat A, Amin MK, Irfan S, Khalid MF, Warraich SZ, Shahzad M. AML-113 Magrolimab efficacy and struggle for approval in acute myeloid leukemia: A systematic review. Clin Lymphoma Myeloma Leuk. 2024;24:S295.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"3312_CR58","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2217\/fon-2022-0975","volume":"19","author":"B Paul","year":"2023","unstructured":"Paul B, Liedtke M, Khouri J, Rifkin R, Gandhi MD, Kin A, Levy MY, Silbermann R, Cottini F, Sborov DW. A phase II multi-arm study of Magrolimab combinations in patients with relapsed\/refractory multiple myeloma. Future Oncol. 2023;19(1):7\u201317.","journal-title":"Future Oncol"},{"key":"3312_CR59","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1182\/blood-2021-153683","volume":"138","author":"K Patel","year":"2021","unstructured":"Patel K, Zonder JA, Sano D, Maris M, Lesokhin A, von Keudell G, Lai C, Ramchandren R, Catalano T, Lin GH. CD47-Blocker TTI-622 shows single-agent activity in patients with advanced relapsed or refractory lymphoma: update from the ongoing first-in-human dose escalation study. Blood. 2021;138:3560.","journal-title":"Blood"},{"issue":"8","key":"3312_CR60","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1158\/1078-0432.CCR-20-3706","volume":"27","author":"SM Ansell","year":"2021","unstructured":"Ansell SM, Maris MB, Lesokhin AM, Chen RW, Flinn IW, Sawas A, Minden MD, Villa D, Percival M-EM, Advani AS. Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2021;27(8):2190\u20139.","journal-title":"Clin Cancer Res"},{"key":"3312_CR61","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2020-134391","volume":"136","author":"J Qi","year":"2020","unstructured":"Qi J, Li J, Jiang B, Jiang B, Liu H, Cao X, Zhang M, Meng Y, Xiaoyu M, Jia Y. A phase i\/iia study of lemzoparlimab, a monoclonal antibody targeting CD47, in patients with relapsed and\/or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): initial phase I results. Blood. 2020;136:30\u20131.","journal-title":"Blood"},{"issue":"1","key":"3312_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46310-y","volume":"15","author":"C Grandcl\u00e9ment","year":"2024","unstructured":"Grandcl\u00e9ment C, Estoppey C, Dheilly E, Panagopoulou M, Monney T, Dreyfus C, Loyau J, Labanca V, Drake A, De Angelis S, Rubod A, Frei J, Caro LN, Blein S, Martini E, Chimen M, Matthes T, Kaya Z, Edwards CM, Edwards JR, Menoret E, Kervoelen C, Pellat-Deceunynck C, Moreau P, Mbow ML, Srivastava A, Dyson MR, Zhukovsky EA, Perro M, Sammicheli S. Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma. Nat Commun. 2024;15(1): 2054.","journal-title":"Nat Commun"},{"issue":"Supplement 1","key":"3312_CR63","doi-asserted-by":"publisher","first-page":"4812","DOI":"10.1182\/blood-2024-208382","volume":"144","author":"M Galeana Figueroa","year":"2024","unstructured":"Galeana Figueroa M, Nyati K, Sharma T, Dhakal B, Mohan M, Hari PN, Venniyil Radhakrishnan S. CD47-CD138 bispecific antibody exhibits selective targeting of multiple myeloma. Blood. 2024;144(Supplement 1):4812\u20134812.","journal-title":"Blood"},{"issue":"Supplement 1","key":"3312_CR64","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.1182\/blood-2024-209952","volume":"144","author":"B Dhakal","year":"2024","unstructured":"Dhakal B, Quach H, Ho PJ, Spencer A, Schroeder MA, Tan P, Cochrane T, Sia H, Zonder JA, Martinet C, Duchesne D, Garton A, Menon V, Holkova B, Konto C, Pacaud L, Kazandjian D. Dose escalation of ISB 1442, a novel CD38 biparatopic x CD47 bispecific antibody, in patients with relapsed \/ refractory multiple myeloma. Blood. 2024;144(Supplement 1):3364\u20133364.","journal-title":"Blood"},{"issue":"6382","key":"3312_CR65","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361\u20135.","journal-title":"Science"},{"issue":"4","key":"3312_CR66","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69.","journal-title":"Blood Cancer J"},{"issue":"4","key":"3312_CR67","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","volume":"34","author":"N Shah","year":"2020","unstructured":"Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34(4):985\u20131005.","journal-title":"Leukemia"},{"issue":"5","key":"3312_CR68","first-page":"332","volume":"20","author":"A Mullard","year":"2021","unstructured":"Mullard A. Blood-brain barrier-traversing biologic secures regulatory approval, in Japan. Nat Rev Drug Discov. 2021;20(5):332.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"3312_CR69","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","volume":"27","author":"MC Da Vi\u00e0","year":"2021","unstructured":"Da Vi\u00e0 MC, Dietrich O, Truger M, Arampatzi P, Duell J, Heidemeier A, Zhou X, Danhof S, Kraus S, Chatterjee M, Meggendorfer M, Twardziok S, Goebeler ME, Topp MS, Hudecek M, Prommersberger S, Hege K, Kaiser S, Fuhr V, Weinhold N, Rosenwald A, Erhard F, Haferlach C, Einsele H, Kort\u00fcm KM, Saliba AE, Rasche L. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nat Med. 2021;27(4):616\u20139.","journal-title":"Nat Med"},{"issue":"1","key":"3312_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-02512-6","volume":"22","author":"Q Lu","year":"2024","unstructured":"Lu Q, Li H, Wu Z, Zhu Z, Zhang Z, Yang D, Tong A. BCMA\/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma. J Nanobiotechnol. 2024;22(1): 279.","journal-title":"J Nanobiotechnol"},{"key":"3312_CR71","doi-asserted-by":"crossref","first-page":"232546","DOI":"10.1155\/2014\/232546","volume":"2014","author":"S de Mel","year":"2014","unstructured":"de Mel S, Lim SH, Tung ML, Chng WJ. Implications of heterogeneity in multiple myeloma. Biomed Res Int. 2014;2014:232546.","journal-title":"Biomed Res Int"},{"issue":"12","key":"3312_CR72","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3324\/haematol.2015.138826","volume":"101","author":"HE Johnsen","year":"2016","unstructured":"Johnsen HE, B\u00f8gsted M, Schmitz A, B\u00f8dker JS, El-Galaly TC, Johansen P, Valent P, Zojer N, Van Valckenborgh E, Vanderkerken K, van Duin M, Sonneveld P, Perez-Andres M, Orfao A, Dybk\u00e6r K. The myeloma stem cell concept, revisited: from phenomenology to operational terms. Haematologica. 2016;101(12):1451\u20139.","journal-title":"Haematologica"},{"issue":"1","key":"3312_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-019-0660-0","volume":"34","author":"M Bhutani","year":"2020","unstructured":"Bhutani M, Foureau DM, Atrash S, Voorhees PM, Usmani SZ. Extramedullary multiple myeloma. Leukemia. 2020;34(1):1\u201320.","journal-title":"Leukemia"},{"issue":"1","key":"3312_CR74","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","volume":"8","author":"L Rasche","year":"2017","unstructured":"Rasche L, Chavan SS, Stephens OW, Patel PH, Tytarenko R, Ashby C, Bauer M, Stein C, Deshpande S, Wardell C, Buzder T, Molnar G, Zangari M, van Rhee F, Thanendrarajan S, Schinke C, Epstein J, Davies FE, Walker BA, Meissner T, Barlogie B, Morgan GJ, Weinhold N. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat Commun. 2017;8(1):268.","journal-title":"Nat Commun"},{"issue":"6","key":"3312_CR75","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/bjh.12175","volume":"160","author":"E Hebron","year":"2013","unstructured":"Hebron E, Hope C, Kim J, Jensen JL, Flanagan C, Bhatia N, Maroulakou I, Mitsiades C, Miyamoto S, Callander N, Hematti P, Asimakopoulos F. MAP3K8 kinase regulates myeloma growth by cell-autonomous and non-autonomous mechanisms involving myeloma-associated monocytes\/macrophages. Br J Haematol. 2013;160(6):779\u201384.","journal-title":"Br J Haematol"},{"issue":"2","key":"3312_CR76","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1634\/theoncologist.2019-0356","volume":"25","author":"MC Da Vi\u00e0","year":"2020","unstructured":"Da Vi\u00e0 MC, Solimando AG, Garitano-Trojaola A, Barrio S, Munawar U, Strifler S, Haertle L, Rhodes N, Teufel E, Vogt C, Lapa C, Beilhack A, Rasche L, Einsele H, Kort\u00fcm K. M., CIC mutation as a molecular mechanism of acquired resistance to combined BRAF-MEK Inhibition in extramedullary multiple myeloma with central nervous system involvement. Oncologist. 2020;25(2):112\u20138.","journal-title":"Oncologist"},{"key":"3312_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.onano.2022.100097","volume":"8","author":"TM Sim","year":"2022","unstructured":"Sim TM. Nanoparticle-assisted targeting of the tumour microenvironment. OpenNano. 2022;8: 100097.","journal-title":"OpenNano"},{"issue":"4","key":"3312_CR78","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/s41591-019-0356-z","volume":"25","author":"ME Logtenberg","year":"2019","unstructured":"Logtenberg ME, Jansen JM, Raaben M, Toebes M, Franke K, Brandsma AM, Matlung HL, Fauster A, Gomez-Eerland R, Bakker NA. Glutaminyl cyclase is an enzymatic modifier of the CD47-SIRP\u03b1 axis and a target for cancer immunotherapy. Nat Med. 2019;25(4):612\u20139.","journal-title":"Nat Med"},{"issue":"9","key":"3312_CR79","doi-asserted-by":"publisher","first-page":"e2368","DOI":"10.1038\/cddis.2016.155","volume":"7","author":"Q Gao","year":"2016","unstructured":"Gao Q, Chen K, Gao L, Zheng Y, Yang Y-G. Thrombospondin-1 signaling through CD47 inhibits cell cycle progression and induces senescence in endothelial cells. Cell Death Dis. 2016;7(9):e2368-2368.","journal-title":"Cell Death Dis"},{"issue":"1","key":"3312_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-020-00930-1","volume":"13","author":"E Eladl","year":"2020","unstructured":"Eladl E, Tremblay-LeMay R, Rastgoo N, Musani R, Chen W, Liu A, Chang H. Role of CD47 in hematological malignancies. J Hematol Oncol. 2020;13(1):1\u201314.","journal-title":"J Hematol Oncol"},{"key":"3312_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/cancers9100139","author":"V Golubovskaya","year":"2017","unstructured":"Golubovskaya V, Berahovich R, Zhou H, Xu S, Harto H, Li L, Chao CC, Mao MM, Wu L. CD47-CAR-T cells effectively kill target cancer cells and block pancreatic tumor growth. Cancers (Basel). 2017. https:\/\/doi.org\/10.3390\/cancers9100139.","journal-title":"Cancers (Basel)"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03312-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03312-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03312-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T22:12:46Z","timestamp":1757455966000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03312-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3312"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03312-6","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]},"assertion":[{"value":"3 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that ethics approval, consent to participate and consent to publish are not applicable for this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1616"}}